Michael Birrer, MD, PhD

Closing out their program on endometrial carcinoma management, key opinion leaders highlight key novel therapeutic strategies in the evolving treatment landscape.

Collaborative discussion on the advent of triplet therapy in patients with metastatic uterine serous carcinoma and clinical data behind this strategy.

Expert Robert L. Coleman, MD, details the final patient case and provides an overview of metastatic uterine serous carcinoma.

Key opinion leaders in the field of endometrial carcinoma provide advice on adverse event management, focusing on immune checkpoint inhibitor therapy.

Robert L. Coleman, MD, and Krishnansu S. Tewari, MD, reflect on data from the GARNET clinical trial of dostarlimab in dMMR recurrent endometrial carcinoma.

Shared insight on the utilization of pembrolizumab in dMMR recurrent endometrial carcinoma in the context of the KEYNOTE-158 clinical trial.

Robert L. Coleman, MD, opens discussion on a second patient case and highlights critical aspects of mismatch repair deficient (dMMR) recurrent endometrial carcinoma.

Before closing out their discussion on the first patient case, key opinion leaders on endometrial carcinoma reflect on the optimal selection and sequencing of therapy in pMMR recurrent disease.

Expert panelists provide their perspective on the real-world use of combination lenvatinib + pembrolizumab in patients with MMRp recurrent endometrial carcinoma.

Moderator Robert L. Coleman, MD, spearheads a review of clinical data from KEYNOTE 775, which combined lenvatinib with pembrolizumab in patients with endometrial carcinoma.

Key opinion leaders in the field of endometrial carcinoma management share advice on optimal patient monitoring and the identification of recurrent disease.

Shared insight on the advent of molecular testing in patients with endometrial carcinoma and how it helps inform the treatment pathway.

Experts Michael J. Birrer, MD, PhD, and Kimberly Halla, MSN, FNP-C, share insight to a typical patient presentation of MMRp recurrent endometrial carcinoma.

Opening its discussion on endometrial carcinoma, a panel of experts led by Robert L. Coleman, MD, reflects on a patient with mismatch repair proficient (MMRp) recurrent disease.

Closing out his discussion on advanced endometrial carcinoma, Michael Birrer, MD, PhD, shares his hope for future treatment advances.

Expert perspectives on Study 309/KEYNOTE-775, which combined pembrolizumab with lenvatinib in patients with advanced endometrial carcinoma.

Insight on the optimal sequencing of therapy in patients with advanced endometrial cancer based on MMR and MSI status.

Michael Birrer, MD, PhD, considers the role of pembrolizumab in advanced endometrial cancer given results from KEYNOTE-158.

A broad look at the systemic and targeted therapies available for patients diagnosed with advanced endometrial carcinoma.

Focused discussion on risk factors that may drive endometrial cancer followed by advice on optimal diagnostic work-up.

Expert perspectives on the work-up and management of a 70-year-old woman who is diagnosed with advanced endometrial carcinoma.

Gynecologic oncology relies on both historical and modern therapies for the treatment of patients with ovarian cancer. During a Targeted Oncology Case-Based Peer Perspective virtual event, Michael J. Birrer, MD, PhD, reviewed the data.

Michael Birrer, MD, PhD, professor of medicine in the Division of Hematology-Oncology, and Director of the Comprehensive Cancer Center at the University of Alabama at Birmingham, discusses current data on predicting response to PARP inhibitor therapy in ovarian cancer.

Michael Birrer, MD, PhD, Director, University of Alabama Comprehensive Cancer Center, discusses adverse event results of the phase III SOLO2 trial, which explored maintenance olaparib (Lynparza) tablets in patients with <em>BRCA</em>-mutated platinum-sensitive relapsed serous ovarian cancer.

Michael Birrer, MD, PhD, director, Medical Gynecologic Oncology Director, Gynecologic Oncology Research Program, Massachusetts General Hospital Cancer Center, professor of Medicine, Harvard Medical School, discusses the current and emerging roles of PARP inhibition in ovarian cancer.

Michael Birrer, MD, PhD, discusses several international phase III trials showing bevacizumab significantly prolonging progression free survival in patients with ovarian cancer.

Michael Birrer, MD, PhD, on treatments targeting either VEGF or ANG2 in gynecologic cancers.

Michael Birrer, MD, PhD, professor of medicine, Harvard Medical School, director, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, discusses other targets in ovarian cancer besides PARP.

Michael Birrer, MD, PhD, discusses the role of PARP inhibitors in ovarian cancer.